Vor Biopharma has appointed Robert Ang to serve as president and CEO. Ang joins Cambridge, MA-based Vor from Neon Therapeutics, where he was chief business officer. His experience also includes positions at Bavarian Nordic, Cadence Pharmaceuticals, and Frazier Healthcare Ventures. In February, Vor raised $42 million in Series A financing to support development of a VOR33, a stem cell treatment in preclinical development for acute myeloid leukemia.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
